OverviewSuggest Edit
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The Company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.
| Type | Private | |
| Founded | 2003 | |
| HQ | Utrecht, NL | Map |
| Website | merus.nl | |
| Employee Ratings | More |
Recent NewsAll News
- Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
- Merus to Participate in William Blair's Biotech Focus Conference 2021
- Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
- Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Key People/Management at Merus
Bill Lundberg
President, Chief Executive Officer & Principal Financial Officer, Executive Director
Andrew Joe
SVP & Chief Medical Officer
Lex Bakker
SVP & Chief Development Officer
John de Kruif
SVP & Chief Technology Officer
Mark Iwicki
Non-Executive Director
Peter B. Silverman
EVP, General Counsel and Head of Utrecht
Merus Office Locations
Merus has offices in Utrecht and Cambridge
Utrecht, NL (HQ)
62 Yalelaan
Utrecht, NL (HQ)
H.R. Kruytgebouw 8 Padualaan
Cambridge, MA, US
139 Main St #302
Merus Financials and Metrics
Summary Metrics
Founding Date | 2003 |
Merus total Funding | $149.3 m |
Merus latest funding size | $79.14 m |
Time since last funding | 6 years ago |
Merus investors | Sofinnova Ventures, Bay City Capital, Novartis Venture Fund, Pfizer Venture Investments, Life Sciences Partners, Rock Springs Capital, Pfizer, Tekla Capital Management, Johnson & Johnson Innovation, Novo A/S, RA Capital Healthcare, Aglaia Oncology Fund |
Merus's latest funding round in April 2015 was reported to be $79.1 m. In total, Merus has raised $149.3 m
Merus Cybersecurity Score
Merus Online and Social Media Presence
Merus's Trends
Merus News and Updates
July 21, 2021
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the novel mechanism of action (MOA) of MCLA-145, t…
July 07, 2021
Merus to Participate in William Blair's Biotech Focus Conference 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer …
June 04, 2021
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across severa…
May 19, 2021
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, with confirmed partial responses in 4 of 10 patients with pancreatic cancer (40%) and in 9 of 33 patients a…
May 13, 2021
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced new collaborations in Israel, Italy and Spain to ex…
May 11, 2021
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer o…
Merus Blogs
May 26, 2021
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., Chief Executive
April 28, 2021
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the
November 09, 2020
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
Content Import
Mon, 11/09/2020 - 08:03
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
November 9, 2020 at 8:00 AM EST
This release …
October 12, 2020
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
Content Import
Mon, 10/12/2020 - 17:00
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical T…
August 06, 2020
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Content Import
Thu, 08/06/2020 - 16:11
Merus Announces Financial Results for the Second Quarter and Provides Business Update
August 6, 2020 at 4:07 PM EDT
This release is a b…
July 27, 2020
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
Content Import
Mon, 07/27/2020 - 08:02
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
July 27, 2020 at 8:00 AM EDT
…
Merus Frequently Asked Questions
When was Merus founded?
Merus was founded in 2003.
Who are Merus key executives?
Merus's key executives are Bill Lundberg, Andrew Joe and Lex Bakker.
How many employees does Merus have?
Merus has 159 employees.
Who are Merus competitors?
Competitors of Merus include Kromaspects Scitec Solutions, Entera Bio and Catalyst Pharmaceuticals.
Where is Merus headquarters?
Merus headquarters is located at 62 Yalelaan, Utrecht.
Where are Merus offices?
Merus has offices in Utrecht and Cambridge.
How many offices does Merus have?
Merus has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies